Quinn Opportunity Partners LLC Boosts Stock Position in uniQure (NASDAQ:QURE)

Quinn Opportunity Partners LLC raised its holdings in uniQure (NASDAQ:QURE - Free Report) by 187.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 69,000 shares of the biotechnology company's stock after purchasing an additional 45,000 shares during the period. Quinn Opportunity Partners LLC owned 0.14% of uniQure worth $1,219,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of QURE. Twin Tree Management LP bought a new stake in uniQure during the 4th quarter valued at $77,000. FNY Investment Advisers LLC purchased a new position in uniQure in the 4th quarter worth approximately $88,000. ADAR1 Capital Management LLC bought a new stake in shares of uniQure during the 4th quarter worth $177,000. China Universal Asset Management Co. Ltd. grew its position in uniQure by 9.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company's stock worth $195,000 after acquiring an additional 969 shares in the last quarter. Finally, Wells Fargo & Company MN increased its stake in uniQure by 13.9% in the fourth quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock valued at $217,000 after acquiring an additional 1,503 shares during the last quarter. Institutional investors own 78.83% of the company's stock.

Analyst Ratings Changes

QURE has been the topic of a number of recent research reports. StockNews.com raised uniQure to a "sell" rating in a research note on Tuesday, March 11th. HC Wainwright reaffirmed a "buy" rating and set a $70.00 price target on shares of uniQure in a report on Tuesday, March 4th. Mizuho raised their price target on uniQure from $7.00 to $20.00 and gave the stock a "neutral" rating in a research note on Thursday, December 19th. Wells Fargo & Company cut their price target on uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a research note on Friday, February 28th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $24.00 target price on shares of uniQure in a report on Tuesday, January 21st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $38.80.

uniQure Stock Performance

QURE traded up $3.83 during trading on Thursday, reaching $13.22. 12,650,362 shares of the company's stock were exchanged, compared to its average volume of 1,297,159. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The company's fifty day simple moving average is $11.91 and its 200-day simple moving average is $11.12. uniQure has a 1 year low of $3.73 and a 1 year high of $19.18. The stock has a market capitalization of $714.90 million, a P/E ratio of -2.67 and a beta of 0.42.

Insider Buying and Selling at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 28,341 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $291,628.89. Following the completion of the sale, the chief executive officer now owns 651,454 shares in the company, valued at approximately $6,703,461.66. This represents a 4.17 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Christian Klemt sold 14,341 shares of the business's stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total value of $153,448.70. Following the transaction, the chief financial officer now owns 152,372 shares in the company, valued at approximately $1,630,380.40. This represents a 8.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 90,830 shares of company stock worth $961,401. Insiders own 4.74% of the company's stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.